ВЛИЯНИЕ ИНГИБИТОРА 5-α-РЕДУКТАЗЫ ПРОСКАРА (ФИНАСТЕРИДА) НА ПРОГРЕССИРОВАНИЕ ДОБРОКАЧЕСТВЕННОЙ ГИПЕРПЛАЗИИ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, УМЕНЬШЕНИЕ РИСКА КРОВОПОТЕРИ И ПРОФИЛАКТИКУ ТУР-СИНДРОМА ВО ВРЕМЯ ТРАНСУРЕТРАЛЬНОЙ РЕЗЕКЦИИ

простата, трансуретральная резекция, финастерид, гемостаз, фибринолиз, послеоперационная кровопотеря

1. Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV et al. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU Int 2005; 96(7): 1045-1048

2. Beckman TJ, Mynderse LA. Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc 2005; 80(10): 1356-1362

3. Logan YT, Belgeri MT. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. Am J Geriatr Pharmacother 2005; 3(2): 103-104

4. Kaplan SA. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. J Urol 2003; 170(1): 341

5. Jimenez Cruz JF, Quecedo Gutierrez L, Del Llano Seсarнs J. Finasteride: 10 years of clinical use. Systematic review of the literature. Actas Urol Esp 2003; 27(3): 202-215

6. Lowe FC, McConnell JD, Hudson PB et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003; 61(4): 791-796

7. Feneley MR, Span PN, Schalken JA et al. A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. Prost Cancer Prost Dis 1999; 2(5/6): 277-281

8. Roehrborn CG, Bruskewitz R, Nickel JC et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 2004; 171(3): 1194-1198

9. Лопаткин НА (ред.). Руководство по урологии. Т. 3 , Медицина, М., 1998

10. Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003; 61(2): 354-8

11. Карпенко ВС, Богатов ОП. Хирургия аденомы предстательной железы. Здоров’я, Киев, 1981

12. Бадалянц ИЮ. Особенности изменения системы гемостаза у больных пожилого и старческого возраста на фоне лечения доброкачественной гиперплазии предстательной железы. Автореф. дис. … канд. мед. наук. Самара, 2000

13. Голощапов ЕТ. Состояние гемокоагуляции у больных аденомой предстательной железы и особенности гемостаза при аденомэктомии.Автореф. дис. … канд. мед. наук. Киев, 1978

14. Новиков ИФ, Александров ВП, Артемов ВВ. Эндоскопические методы лечения урологических больных.СПб,2002

15. Corradi LS, Gіes RM, Carvalho HF, Taboga SR. Inhibition of 5-alpha-reductase activity induces stromal remodeling and smooth muscle de-differentiation in adult gerbil ventral prostate. Differentiation 2004; 72(5): 198-208

16. Erdoru T, Ciftcioglu MA, Emreoglu I et al. Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia. Urol Int 2002; 69(4): 287-292

17. Kamalov AA, Riaboi AV, Ignashin NS et al. Use of proscar in preoperative preparation of patients with benign prostatic hyperplasia before transureteral resection. Urologiia 2002; (5): 16-18

18. Chiu KY, Yong CR. Effects of finasteride on prostate volume and prostate-specific antigen. J Chin Med Assoc 2004; 67(11): 571-574

19. Лопаткин НА. Осложненная аденомэктомия и ТУР предстательной железы. В: Доброкачественная гиперплазия предстательной железы.М., 1999; 210-214

20. Crea G, Sanfilippo G, Anastasi G et al. Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol Int, 2005; 74(1): 51-53

21. Hagerty JA, Ginsberg PC et al. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 2000; 55(5): 684-689

22. Bell CR, Cox DJ et al. Thromboelastographic evaluation of coagulation in transurethral prostatectomy. Br J Urol 1996; 78(5): 737-41

23. Ozdal OL, Ozden C, Benli K et al. Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prost Cancer Prost Dis 2005; 8: 215-218

24. Lund L, Mёller Ernst-Jensen K, Tёrring N, Erik Nielsen J. Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. Scand J Urol Nephrol 2005; 39(2): 160-162

25. Donohue JF, Barber NJ. How do we investigate haematuria and what role has finasteride? BJU Int 2004; 93(1): 3-4

26. Kashif KM, Foley SJ, Basketter V, Holmes SA. Haematuria associated with BPH-Natural history and a new treatment option. Prost Cancer Prost Dis 1998; 1(3): 154-156

27. Donohue JF, Sharman H et al. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J Urol 2002; 168(5): 2024–2026

28. Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 2001; 58(6): 972-976

29. Palou Redorta J, Gausa Gascon L, Salvador Bayarre J et al. Efficacy of finasteride in the treatment of hematuria associated with benign prostatic hypertrophy. Arch Esp Urol 2002; 55(8): 895-899

30. Мартов АГ, Румянцев ВБ, Ермаков ДВ, Зубилин АМ. Синдром водной интоксикации организма («ТУР-синдром»). Урология и нефрология 1999; (4): 44-49

31. Li GH, He ZF, Yu DM et al. Effect of finasteride on intraoperative bleeding and irrigating fluid absorption during transurethral resection of prostate: a quantitative study. Zhejiang Da Xue Xue Bao Yi Xue Ban 2004; 33(3): 258-260

32. Ozmen S, Kosar A et al. Effect of transutethral resection of the prostate on blood coagulation test results. Urol Int 2003; 70(1): 27-30

33. Haggstrom S, Torring N, Moller K et al. Effects of finasteride on vascular endothelial growth factor. Scand J Urol Nephrol 2002; 36(3):182-187

34. Liu XD, Li H, Bu H et al. Effects of finasteride on capillary in the ventral prostate of rat. Sichuan Da Xue Xue Bao Yi Xue Ban 2004; 35(2): 226-228

35. Pareek G, Shevchuk M, Armenakas NA et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003; 169(1): 20-23

36. Donohue JF, Hayne D, Karnik U et al. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int 2005; 96(9): 1319-1322

37. Kaya C, Ozyurek M, Turkeri LN. Comparison of microvessel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: a preliminary study. Int J Urol 2005; 12(2): 194-198